Psychiatric News 2010;45(3):3.
This newsletter article describes two National Drug Abuse Treatment Clinical Trials Network (CTN) protocols that investigated the use of stimulants in treatment of attention-deficit/hyperactivity disorder (ADHD) in patients with concurrent substance use disorder. Protocol CTN-0029 looked at the use of OROS-methylphenidate (Concerta) in adult smokers with ADHD. Over the course of the study, the participants' ADHD symptoms improved significantly more in the methylphenidate group than in the placebo group, however the ADHD treatment had very little effect on smoking cessation outcomes. The adolescent study, CTN-0028, designed to test the effect of ADHD treatment on substance use disorders in adolescents, found no statistically significant difference between the methylphenidate group and the placebo group. However, ADHD symptoms and substance use were reduced for both groups, leading the researchers to hypothesize strong therapeutic effect from the background cognitive-behavioral therapy (CBT) all participants received. Though the methylphenidate-treated participants in both studies had higher rates of adverse events, such as abdominal discomfort, increased heart rate, and nervousness, than placebo-treated participants, there were no signs of worsening smoking or substance use associated with the stimulant. Psychosocial interventions appear to work well for patients with concurrent substance use disorder and ADHD, while ADHD treatment with stimulants does not seem to worsen substance use. (Newsletter article, PDF, English, 2010)
Keywords: Adolescents | Attention Deficit Hyperactivity Disorder (ADHD) | Behavior therapy | Community health services | Concerta | Co-occurring disorders | Nicotine replacement therapy | Osmotic-Release Methylphenidate (OROS-MPH) | Pharmacological therapy | Smoking | Psychiatric News (newsletter)
Document No: 534
Submitted by CTN Dissemination Librarians, 10/5/2010.